Tomoyuki Hayamizu
Research Subjects
Research Interests
Tomoyuki Hayamizu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kazumasa Kamei
Pfizer Japan Inc. Tokyo Japan
2 shared publications - Naohiro Yonemoto
Department of Biostatistics, Faculty of Medicine, University of Toyama, Toyama, Japan
2 shared publications Camille Moyon
Putnam
1 shared publicationCatriona Crossan
Putnam
1 shared publication- Jeffrey Vietri
Pfizer Inc., Collegeville, PA 19426, USA
1 shared publication - Johnna Perdrizet
Global Value and Evidence, Pfizer Canada, Kirkland, Canada
1 shared publication
Latest Publications
- Open Access
- 9 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 546-560
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan. Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
- 9 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 546-560
Open AccessCost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan. Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
- Open Access
- 2 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 485-497
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
The Japanese National Immunization Program currently includes the pediatric 13valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pediatric vaccine versus PCV13. A decision-analytic Markov model was used to estimate expected costs, qualityadjusted life-years (QALYs), and prevented cases and deaths caused by invasive pneumococcal disease, pneumonia, and acute otitis media over a ten-year time horizon from the societal and healthcare payer perspectives. PCV20 (price: 8,102 Japanese yen [JPY]) was dominant, i.e. less costly and more effective, over PCV13 (gained 294,599 QALYs and reduced JPY 352.6 billion [2.6 billion United States dollars, USD] from the societal perspective and JPY 178.9 billion [USD 1.4 billion] from the payer perspective). Sensitivity and scenario analyses validated the robustness of the base scenario results. When comparing PCV20 with PCV13, the threshold analysis revealed an incremental cost-effectiveness ratio that was within the threshold value (JPY 5 million/QALY) at a maximum acquisition price of JPY 74,033 [USD 563] (societal perspective) and JPY 67,758 [USD 515] (payer perspective). As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.
- 2 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 485-497
Open AccessCost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
The Japanese National Immunization Program currently includes the pediatric 13valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pediatric vaccine versus PCV13. A decision-analytic Markov model was used to estimate expected costs, qualityadjusted life-years (QALYs), and prevented cases and deaths caused by invasive pneumococcal disease, pneumonia, and acute otitis media over a ten-year time horizon from the societal and healthcare payer perspectives. PCV20 (price: 8,102 Japanese yen [JPY]) was dominant, i.e. less costly and more effective, over PCV13 (gained 294,599 QALYs and reduced JPY 352.6 billion [2.6 billion United States dollars, USD] from the societal perspective and JPY 178.9 billion [USD 1.4 billion] from the payer perspective). Sensitivity and scenario analyses validated the robustness of the base scenario results. When comparing PCV20 with PCV13, the threshold analysis revealed an incremental cost-effectiveness ratio that was within the threshold value (JPY 5 million/QALY) at a maximum acquisition price of JPY 74,033 [USD 563] (societal perspective) and JPY 67,758 [USD 515] (payer perspective). As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.